drug · antibody drug conjugate
trastuzumab pamirtecan
Phase 3updated 6mo agoby $BNTX BioNTech SE🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Unknown, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
News(5)
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 3d ago
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.biopharma_dive · 19d ago
- BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer resultsBioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant, yet modes…endpoints · 19d ago
- BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD casesBioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to conclude its HER2-directed candidate may offer limited benefits in the…fiercebiotech · 19d ago
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that